Open AccessP1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
Author(s) -
Fedorova L.,
Lepik K.,
Mikhailova N.,
Kondakova E.,
Komarova Y.,
Popova M.,
Kotselyabina P.,
Borzenkova E.,
Baykov V.,
Moiseev I.,
Kulagin A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847188.87255.f7
Subject(s) - nivolumab , medicine , refractory (planetary science) , lymphoma , prospective cohort study , progression free survival , adverse effect , toxicity , gastroenterology , cohort , oncology , chemotherapy , immunotherapy , cancer , physics , astrobiology